Description
Humana Heart Disease And Erectile Dysfunction by Robert A. Kloner
Senior physicians, cardiologists, urologists, psychologists, and pharmacologists critically review the relation between heart disease and erectile dysfunction (ED) and explain for the practicing physician the effective new treatment options available for the cardiac patient with ED. The authors detail in concise language the latest thinking about the risk of sexually induced cardiac events, the efficacy and risks to cardiac patients of drugs used to treat sexual dysfunction, and the expert guidelines developed by prominent organizations on the optimal approach to sexual dysfunction in the cardiac patient. They also discuss the physiology of ED and the currently available therapies (sildenafil, tadalafil, and vardenafil) may interact with the cardiac system, and the potential application of newer agents like phosphodiesterase-5 inhibitors to cardiovascular disease. Physiology of Erection and Causes of Erectile DysfunctionAristotelis G. Anastasiadis, Dmitry Droggin, Martin Burchardt, and Ridwan ShabsighErectile Dysfunction: The Scope of the ProblemCulley C. CarsonErectile Dysfunction and Cardiovascular Risk FactorsRobert A. KlonerPsychologic Aspects of Erectile Dysfunction in Heart PatientsRaymond C. RosenManagement of Erectile Dysfunction: An OverviewHarin Padma-NathanSildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling PathwayIan H. Osterloh and Stephen C. PhillipsPhosphodiesterase-5 Inhibition: Importance to the Cardiovascular SystemJackie D. Corbin, Stephen R. Rannels, and Sharron H. FrancisThe Hemodynamics of Phosphodiesterase-PDE5 InhibitorsGraham JacksonCardiovascular Safety of Phosphodiesterase-5 InhibitorsRobert A. KlonerEffect of Phosphodiesterase-5 Inhibition on Coronary Blood Flow in Experimental AnimalsYingJie Chen, Jay H. Traverse, and Robert J. BacheSafety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery DiseaseSameer Rohatgi and Howard C. HerrmannCardiovascular Effects of Nonphosphodiesterase-5 Inhibitor Erectile Dysfunction TherapiesHarin Padma-NathanPotential Cardiac Applications of Phosphodiesterase Type-5 InhibitionMichael Sweeney and Richard L. SiegelThe Physiologic Cost of Sexual ActivityRobert F. DeBuskSexual Activity As a Trigger of Myocardial Infarction/Ischemia: Implications for Treating Erectile DysfunctionRobert A. KlonerSex After Cardiac Events and Procedures: Counseling From the Cardiovascular Specialist's PerspectiveHerman A. Taylor, Jr.American College of Cardiology/American Heart Association Guidelines on the Use of Sildenafil in Patients With Cardiovascular DiseaseAdolph M. Hutter, Jr.Risk of Heart Attack After Sexual Activity: The Princeton Guidelines and Their RationaleRobert F. DeBuskIndex